AlphaGrep UK Ltd’s Haemonetics HAE Stock Holding History

AlphaGrep UK Ltd’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,847	Closed	-$308K	–	850
2025 Q4	$308K	Buy	+3,847	New	+$258K	0.1%	414

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AlphaGrep UK Ltd's HAE Position: Q1 2026 in Review

AlphaGrep UK Ltd sold out of Haemonetics (HAE) in Q1 2026, closing a stake of 3,847 shares — an estimated $308K sold.

AlphaGrep UK Ltd first reported a position in HAE in Q4 2025 and held it in 1 quarter. The position peaked at $308K in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

AlphaGrep UK Ltd reported no remaining Haemonetics position as of Q1 2026 after selling out during the quarter.
AlphaGrep UK Ltd sold 3,847 Haemonetics shares in Q1 2026, an estimated $308K.
AlphaGrep UK Ltd first reported a position in Haemonetics in Q4 2025 and held it in 1 quarter.
AlphaGrep UK Ltd's Haemonetics position peaked at $308K in Q4 2025.
324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.